Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

A notable development is the termination of IGM’s collaboration with Sanofi (NYSE:NASDAQ:SNY), which has raised concerns about the company’s partnerships and future prospects. In response to ...

On Monday, IGM Biosciences, Inc., a pharmaceutical company based in Mountain View, California, announced the termination of a significant collaboration and license agreement with Genzyme Corporation, ...

IGM still has an immunology research partnership with biotech giant Sanofi, but the cuts to imvotamab and the other antibody leave the firm without any other projects in its listed pipeline.

MORRISTOWN, N.J. and CAMBRIDGE, Mass., May 14, 2025 /PRNewswire/ -- Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment ...

The end of IGM’s collaboration with Sanofi represents a significant setback. Such partnerships often provide smaller biotech firms with financial support, research and development resources, and ...

The partnership with Sanofi, which focuses on IgM-based agonists targeting autoimmune and inflammatory diseases, includes three preclinical candidates with potential milestone payments exceeding ...